The progress of chronic renal disease patients followed by the diagnosis of COVID-19 in ICU

Abstract

Aim: The mortality and morbidity of COVID-19 disease are higher in patients with comorbidities. In this study, we staged patients with chronic renal failure hospitalized in the intensive care unit (ICU) and aimed to evaluate the process of the disease according to the stage of failure.
 Material and Method: The medical records of 249 patients followed in Ankara City Hospital MH3 ICU were reviewed retrospectively. The patients were divided into three stages according to their estimated glomerular filtration rate (e-GFR) value (stage 1: e-GFR≥90 ml/min/1.73 m², stage-2: e-GFR: 15-89 ml/min/1.73 m², stage- 3: e-GFR≤15 ml/min/1.73 m²). Data such as age, gender, comorbidity status, length of stay in the ICU, duration of mechanical ventilation, and mortality rate of the patients were recorded. Patients who were evaluated as stage-2 were also classified into 3 stages (stage-2a: e-GFR: 60-89 ml/min/1.73 m², stage-2b: e-GFR:30-59 ml/min/1.73 m², stage-2c: e-GFR: 15-29 ml/min/1.73 m²) and evaluated with the same parameters.
 Results: The mean age of all patients was 71 years. It was found that the intubation rate was higher (p=0.012) and the mortality rate was higher (p=0.003) in patients evaluated as stage-3. APACHE II and SOFA scores were higher than the other groups (p=

Extra corporeal membrane oxygenation therapy in acute respiratory distress syndrome due to Coronavirus-2019 (COVID-19): a retrospective study

“…Other factors, such as chronic lung disease, longer symptom duration, and longer duration of invasive mechanical ventilation, in addition to precannulation factors, such as higher arterial CO2 partial pressure, higher driving pressure, and less ECMO experience, were also noted. In the study of Uysal et al 19 it was stated that the mortality rate in COVID-19 patients with chronic renal failure hospitalized in intensive care is high, and as the severity of the disease increases, the rate of patients being connected to mechanical ventilation and death increases.In our study, prognostic factors for high mortality included comorbidities, male gender, long symptom duration, and mechanical ventilation duration.…”

Comparison of clinical outcomes of intensive care patients with COVID-19 pneumonia receiving and not receiving tocilizumab treatment

“…Coronavirus disease 2019 (COVID- 19) is an infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high morbidity and mortality and impairing quality of life (1,2). The first case of pneumonia due to COVID-19 emerged in December 2019 in Wuhan city of China's Hubei province (3). The World Health Organization (WHO) declared a pandemic on March 11, 2020, after the disease spread rapidly around the world and cases emerged on all continents (4).…”